Dyadic International (DYAI) Investor presentation summary

Platform overview and technology

• Rapid, scalable microbial platform enables animal-free protein production for life sciences, diagnostics, and biomanufacturing.

• Engineered C1 fungal strain supports high-yield, low-viscosity fermentation and humanized glycosylation.

• Stable production strains can be generated in as little as three weeks, significantly faster than traditional CHO systems.

• Industrial-scale fermentation validated at >100,000L, using standard equipment and fed-batch technology.

• Platform supports a wide range of biologics, including vaccine antigens, monoclonal antibodies, and complex proteins.

Performance, productivity, and cost advantages

• C1 platform offers cell doubling time of ~2.5 hours and production cycles of 7–9 days, outperforming CHO and insect systems.

• Achieves up to 10–40x higher yields than baculovirus systems and multi-gram per liter titers in 4–7 days.

• Lower cost of goods due to rapid fermentation, high productivity, and no need for viral clearance steps.

• Multiple engineering strategies, including combinatorial libraries and fermentation optimization, have demonstrated 6–8x productivity improvements.

• Humanized glycosylation patterns achieved with >98% humanized glycans and >92% occupancy.

Safety, regulatory, and clinical validation

• C1 host is non-pathogenic, FDA GRAS, with no mammalian viral contamination risk and a controlled impurity profile.

• Platform purification processes are comparable to other biologics, and safety demonstrated in successful Phase I clinical trial.

• Comparability confirmed between GLP and GMP batches for vaccine candidates, with all parameters within acceptance criteria.

• Phase I study of DYAI-100 vaccine met primary safety endpoint and induced robust immune responses.